KALY Recommended A BUY At $0.01 With Potential To $0.10 After $5 Million CBD Extraction Contract Announcement
June 05 2019 - 9:16AM
InvestorsHub NewsWire
KALY Recommended A BUY At $0.01
With Potential To $0.10 After $5 Million CBD Extraction Contract
Announcement
New York, NY -- June 5, 2019 --
InvestorsHub NewsWire -- via
www.nextbigticker.com -- Kali-Extracts, Inc. (USOTC:
KALY) is recommended a BUY today by AmericanBulls (americanbulls.com/KALY). Yesterday, the
company announced a CBD extraction contraction with a licensed hemp
grower in the State of New York that is worth a potential $5
million dollars driving the company’s overall potential revenue in
2019 to $6 million.
AmericanBulls says
…
“Let’s jump on
our white horses and go for a bullish ride. The bullish pattern
that was previously identified is finally confirmed and
a BUY signal is generated. Most probably, it is the
right time to participate in bullish fervor. The market is telling
you about a new profit. Do not miss this bullish
opportunity.”
Last Signal: BUY
Last Pattern: BULLISH DOJI STAR
KALY Potential PPS
Run From $0.01 to $0.04 On Way To
$0.10
The KALY PPS experienced a dramatic dip on
Monday following Friday’s FDA non-committal comments on CBD and
then rebounded on high volume on Tuesday. Now KALY has a buy
recommendation and is still below the almost $0.04 high it reached
late last year after acquiring the US Patented Cannabis Extraction
Process that is currently the center of the company’s growing
value. With KALY’s patented cannabis pharmaceutical research
now coming to light, the PPS is positioned to shoot past the recent
$0.04 highs to a level putting it on par with some of the other
penny cannabis stock contenders. A $0.10 PPS is not an
unreasonable milestone after singing a $5 million CBD extraction
contract.
KALY is providing CBD extracts for over $1
million worth of CBD infused water produced by Puration, Inc.
(USOTC:
PURA), and KALY has also introduced its own CBD infused gum,
Hemp4mula available on North American Cannabis Holdings, Inc.’s
website www.USMJ.com. KALY is also implementing an
extraction lab to process biomass from Nouveau’s (USOTC:
NOUV) 100 acer hemp farm.
Following the acquisition of the patented
cannabis extraction process late last year and the corresponding
jump in price and trading volume, the OTC Markets flagged the
company in response to the jump in activity. The company has
responded by updating all its OTC Markets required reports.
Management is likely to mitigate the OTC Market’s concerns sooner
or later and see the flag removed which will likely be yet another
impetus fueling a KALY PPS
run.
Management engaged Goldman Small Cap
Research to conduct analyst coverage of the company and file an
initial analyst report: KALY Research
Report
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not
occur.
Source: www.nextbigticker.com
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Apr 2023 to Apr 2024
